Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.


California Life Sciences Association (CLSA) Responds to Administration’s Drug Importation Plan


California Life Sciences Association (CLSA), the trade association representing Californias life sciences sector, issued the following statement in response to the Trump Administrations drug importation proposal unveiled today. This statement can be attributed to Mike Guerra, President & CEO, CLSA:

The Trump Administrations plan to allow for the importation of foreign drugs is unworkable, compromises the health and safety of Americans, and wont bring savings to patients pocketbooks. Former top officials from both Republican and Democratic Presidential Administrations have previously warned about safety concerns related to and the inability of federal agencies, such as FDA, CMS, DEA and FBI, to conduct adequate oversight of drug importation. Unfortunately, this flawed proposal takes a step in the wrong direction. Instead of pursuing a faulty plan that could exacerbate drug shortages worldwide, we should work to cap out-of-pocket costs so that patients have more predictability and are able to afford the treatments they need.

On behalf of Californias life sciences sector, a vibrant ecosystem working to develop thousands of safe and effective new treatments to help patients, we urge the Administration to abandon this flawed proposal that could compromise patient safety. We will also work diligently with our bipartisan California Congressional delegation to educate them on the shortcomings of this plan.

Click here to read the proposal.

  • Learn More about the California life sciences sector
  • View CLSAs Legislative Action Center
  • Watch CLSAs Faces of California Biomedical Innovation Web Series
  • View Upcoming CLSA events
  • Meet the CLSA Board of Directors

About California Life Sciences Association (CLSA)

California Life Sciences Association (CLSA) is the states largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow Californias life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.

California Life Sciences Association (CLSA)

Will Zasadny | Director, Communications | 619-961-8848


Editorial & Advertiser disclosure

Call for Entries

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Newsletters with Secrets & Analysis. Subscribe Now


Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.